DRDiego Ruiz-Avila

Diego Ruiz-Avila

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Diego Ruiz-Avila has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patient-Reported Anxiety and Cross-Sectional Classification of Heart Failure Functional Status Beyond Electronic Medical Record Data: A Feasibility Pilot Study (Preprint)

    by Ismail EL Moudden, Semimo Adeleke, Diego Ruiz-Avila, Clare Chen, Teresa Lynch, Marlene Robles, Sudhir Mungee, Jacob Wurster, Sunita Dodani

    BACKGROUND Assessment of New York Heart Association (NYHA) functional class in heart failure (HF) has relied on electronic medical record (EMR) data, omitting psychosocial determinants now collectible through patient-facing applications. OBJECTIVE This study aimed to assess the feasibility of collecting measures of anxiety, perceived social support, and health literacy through a patient-facing digital health application and to determine whether these measures improve identification of advanced NYHA functional limitation beyond EMR data in adults with HF. METHODS This single-center cross-sectional feasibility pilot study enrolled adults with HF in inpatient and outpatient settings. Clinical data came from the EMR and patient-reported measures from the application. The originally specified 30-day readmission outcome yielded a single event, so the primary outcome was self-reported NYHA Class III-IV versus Class I-II, assessed concurrently with the predictors. Stage 1 used prespecified EMR variables (age, sex, HF duration, comorbidity count, guideline-directed medical therapy, and diuretic use); Stage 2 added the patient-reported measures. Logistic regression, elastic net, random forest, and gradient-boosted tree models were evaluated for discrimination, calibration, Brier score, and reclassification using repeated cross-validation, nested cross-validation, bootstrap optimism correction, and sensitivity analyses. RESULTS Of 100 consented participants, 93 were analyzed, and 42 (45%) reported NYHA Class III-IV. Core application instruments were completed by 92%-93% of consented participants. The Stage 2 elastic net (primary model) achieved a cross-validated area under the receiver operating characteristic curve (AUC) of 0.66 (95% confidence interval [CI] 0.55-0.77) versus 0.57 (95% CI 0.45-0.70) for Stage 1, and the primary test was nonsignificant (AUC difference +0.09; DeLong P=.09). The continuous net reclassification improvement was 0.45 (95% CI 0.08-0.83), but its event component was zero for both linear models. Two tree-based comparators reached nominal significance (P=.003 and P=.007) but were not considered confirmatory: the random forest EMR-only AUC was at chance (0.49), and gradient-boosted tree calibration and Brier score worsened with the added predictors. Under nested cross-validation, the Stage 2 elastic net AUC was 0.62, with a mean per-repeat increment of +0.10, and the bootstrap optimism-corrected Stage 2 AUC was 0.69. In multiply imputed multivariable logistic regression, the Generalized Anxiety Disorder 7-item scale score was the only significant patient-reported predictor (odds ratio 1.15 per point, 95% CI 1.02-1.30; P=.02). CONCLUSIONS In this cross-sectional feasibility pilot study, completion of the application-collected instruments was high, but adding the patient-reported measures to EMR-derived clinical variables produced a numerical, nonsignificant improvement in discrimination of advanced self-reported NYHA functional limitation. Anxiety was the only patient-reported measure with an individual association across several analytic approaches, although this association was not uniformly robust and interpretation is limited by concurrent collection of predictor and outcome through the same application. Larger multisite studies with independently assessed functional outcomes and external validation are needed.

  • Open Access

    Can Patient-Reported Anxiety Improve Prediction of Heart Failure Functional Status Beyond Electronic Medical Record Data? A Pilot Observational Study (Preprint)

    by Ismail EL Moudden, Semimo Adeleke, Diego Ruiz-Avila, Clare Chen, Teresa Lynch, Marlene Robles, Sudhir Mungee, Jacob Wurster, Sunita Dodani

    BACKGROUND Prediction of New York Heart Association (NYHA) functional class in heart failure (HF) has relied on electronic medical record (EMR) data, omitting psychosocial determinants now collectible through patient-facing applications. OBJECTIVE This study aimed to determine whether patient-reported measures of anxiety, perceived social support, and health literacy, collected through a patient-facing digital health application, improve identification of advanced NYHA functional limitation beyond routinely available EMR data in adults with HF. METHODS Single-center pilot observational study of adults with HF receiving care in inpatient and outpatient settings. Clinical and demographic data were obtained from the EMR; patient-reported measures were collected through a patient-facing digital health application. The primary outcome was self-reported NYHA Class III-IV versus Class I-II. A two-stage framework compared Stage 1, comprising prespecified EMR-derived variables (age, sex, HF duration, comorbidity burden, guideline-directed medical therapy, and diuretic use), with Stage 2, which added the patient-reported measures. Logistic regression, elastic-net, random forest, and gradient-boosted tree models were evaluated using discrimination, calibration, reclassification, and prediction-error measures with repeated cross-validation and sensitivity analyses. RESULTS The Stage 2 elastic net (primary model) achieved cross-validated AUC 0.66 (95% CI 0.55, 0.77) versus Stage 1 (EMR-only) AUC 0.57 (0.45, 0.70); the primary incremental-discrimination test was non-significant (AUC difference +0.09, DeLong p = 0.094). In exploratory analyses, the continuous NRI was 0.45 (95% CI 0.08, 0.83), but its event component was zero for both linear models. Two tree-based comparators reached nominal DeLong significance (p = 0.003, p = 0.007) but were not considered confirmatory: the random-forest EMR-only baseline was at chance (AUC 0.49), and gradient-boosted-tree calibration and Brier score worsened with the added predictors. Under fully nested cross-validation the elastic-net Stage 2 AUC was 0.62 with a repeat-level increment of +0.10 (2.5-97.5 percentile range across repeats 0.02 to 0.16), and the bootstrap optimism-corrected Stage 2 AUC was 0.69. In MICE-pooled multivariable logistic regression, GAD-7 was the only individually significant predictor (OR 1.15 per point, 95% CI 1.02 to 1.30, p = 0.022). CONCLUSIONS In this single-center pilot observational study, adding patient-reported psychosocial measures to routinely available EMR-derived clinical variables produced a numerical but statistically nonsignificant improvement in discrimination of advanced self-reported NYHA functional limitation. Anxiety was the only patient-reported measure with a consistent individual association across analytic approaches, although interpretation is limited by concurrent collection of predictor and outcome through the same application. Larger multisite studies with independently assessed functional outcomes and external validation are needed to determine whether patient-generated psychosocial data add meaningful incremental value for HF risk stratification.

  • Open Access

    Figure S4 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models

    by Frederick Nguele Meke, Yunpeng Bai, Diego Ruiz-Avila, Colin Carlock, Jinan Ayub, Jinmin Miao, Yanyang Hu, Qinglin Li, Zhong-Yin Zhang

    Prl2 deletion upregulates PTEN to inhibit Akt signaling and hinder tumor cell proliferation in Tp53 heterozygous mice

  • Open Access

    FIGURE 3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models

    by Frederick Nguele Meke, Yunpeng Bai, Diego Ruiz-Avila, Colin Carlock, Jinan Ayub, Jinmin Miao, Yanyang Hu, Qinglin Li, Zhong-Yin Zhang

    Prl2 deletion enhances survival and hinders tumor growth rate in tamoxifen-inducible Tp53−/− mouse but does not affect tumor initiation. A, PCR genotyping to identify different genotypes in the study. B, Kaplan–Meier survival plot for thymic lymphoma-free survival in tamoxifen-inducible Tp53−/− n = 43 and inducible Tp53−/−; Prl2−/− n = 33. C, Bar graph representing percent tumor incidence in inducible Tp53−/− background with or without inducible Prl2 deletion. Dot plots representing: The mass of thymus/thymic lymphoma over time in inducible Tp53−/− n = 9–20 per timepoint and inducible Tp53−/−; Prl2−/− n = 8–14 per timepoint (D). E, Thymocyte population ratios 9 weeks after inducing Tp53 deletion with or without Prl2 deletion. F, Thymocyte population ratios 12 weeks after inducing Tp53 deletion with or without Prl2 deletion. DP: Double positive (CD4+ CD8+). DN: Double negative (CD4− CD8−). log-rank test performed for Kaplan–Meier survival curves and Student t test performed for all other analysis. Data are shown as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

  • Open Access

    FIGURE 5 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models

    by Frederick Nguele Meke, Yunpeng Bai, Diego Ruiz-Avila, Colin Carlock, Jinan Ayub, Jinmin Miao, Yanyang Hu, Qinglin Li, Zhong-Yin Zhang

    Prl2 deletion upregulates PTEN to inhibit Akt signaling and hinder tumor cell proliferation in inducible Tp53−/− mice. A, Representative Western blot analysis from inducible Tp53−/− and inducible Tp53−/−; Prl2−/−–derived thymic lymphomas to determine expression of PTEN, PUMA, BAX, p21, cyclin D1, p27, as well as the expression and activation of Akt and Akt targets. The actin loading control shown is the same as that in Fig. 4A. B, Dot plot for quantification of PTEN and Akt activation. C, Dot plot for quantification of Western blot analysis for the activation of Akt targets mTOR and GSK3β. D, Dot plot for quantification of the expression of Tp53 targets PUMA, BAX, p21, and cyclin D1. E, Dot plot for quantification of FoxOs activation and p27 expression. Data shown as mean ± SEM for samples obtained 12 weeks after tamoxifen treatment, Tp53−/− n = 10–20, Tp53−/−; Prl2−/− n = 10–14; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.

  • Open Access

    Figure S3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models

    by Frederick Nguele Meke, Yunpeng Bai, Diego Ruiz-Avila, Colin Carlock, Jinan Ayub, Jinmin Miao, Yanyang Hu, Qinglin Li, Zhong-Yin Zhang

    Prl2 deletion inhibits tumor cell proliferations

  • Open Access

    FIGURE 5 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models

    by Frederick Nguele Meke, Yunpeng Bai, Diego Ruiz-Avila, Colin Carlock, Jinan Ayub, Jinmin Miao, Yanyang Hu, Qinglin Li, Zhong-Yin Zhang

    Prl2 deletion upregulates PTEN to inhibit Akt signaling and hinder tumor cell proliferation in inducible Tp53−/− mice. A, Representative Western blot analysis from inducible Tp53−/− and inducible Tp53−/−; Prl2−/−–derived thymic lymphomas to determine expression of PTEN, PUMA, BAX, p21, cyclin D1, p27, as well as the expression and activation of Akt and Akt targets. The actin loading control shown is the same as that in Fig. 4A. B, Dot plot for quantification of PTEN and Akt activation. C, Dot plot for quantification of Western blot analysis for the activation of Akt targets mTOR and GSK3β. D, Dot plot for quantification of the expression of Tp53 targets PUMA, BAX, p21, and cyclin D1. E, Dot plot for quantification of FoxOs activation and p27 expression. Data shown as mean ± SEM for samples obtained 12 weeks after tamoxifen treatment, Tp53−/− n = 10–20, Tp53−/−; Prl2−/− n = 10–14; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.

  • Open Access

    Figure S2 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models

    by Frederick Nguele Meke, Yunpeng Bai, Diego Ruiz-Avila, Colin Carlock, Jinan Ayub, Jinmin Miao, Yanyang Hu, Qinglin Li, Zhong-Yin Zhang

    Experiemental design for tamoxifen inducible Tp53 deletion w/o Prl2 deletion

  • Open Access

    FIGURE 3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models

    by Frederick Nguele Meke, Yunpeng Bai, Diego Ruiz-Avila, Colin Carlock, Jinan Ayub, Jinmin Miao, Yanyang Hu, Qinglin Li, Zhong-Yin Zhang

    Prl2 deletion enhances survival and hinders tumor growth rate in tamoxifen-inducible Tp53−/− mouse but does not affect tumor initiation. A, PCR genotyping to identify different genotypes in the study. B, Kaplan–Meier survival plot for thymic lymphoma-free survival in tamoxifen-inducible Tp53−/− n = 43 and inducible Tp53−/−; Prl2−/− n = 33. C, Bar graph representing percent tumor incidence in inducible Tp53−/− background with or without inducible Prl2 deletion. Dot plots representing: The mass of thymus/thymic lymphoma over time in inducible Tp53−/− n = 9–20 per timepoint and inducible Tp53−/−; Prl2−/− n = 8–14 per timepoint (D). E, Thymocyte population ratios 9 weeks after inducing Tp53 deletion with or without Prl2 deletion. F, Thymocyte population ratios 12 weeks after inducing Tp53 deletion with or without Prl2 deletion. DP: Double positive (CD4+ CD8+). DN: Double negative (CD4− CD8−). log-rank test performed for Kaplan–Meier survival curves and Student t test performed for all other analysis. Data are shown as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

  • Open Access

    Figure S5 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models

    by Frederick Nguele Meke, Yunpeng Bai, Diego Ruiz-Avila, Colin Carlock, Jinan Ayub, Jinmin Miao, Yanyang Hu, Qinglin Li, Zhong-Yin Zhang

    Prl2 deletion does not affect Erk activation in inducible Tp53-/- mice derived thymic lymphomas